skip to main content
Idioma:
Primo Search
Clear Search Box
Search in: Busca Geral
Busca Avançada
Busca por Índices
Tipo de recurso Mostra resultados com: Mostra resultados com: Índice

Future of investigational drugs databases—Part 2 —Comparison of the functionalities and survey of the trend of use— No.2

21, PINET

Journal of Information Processing and Management, 2005, Vol.48(1), pp.7-15

Japan Science and Technology Agency

Texto completo disponível

Citações Citado por
  • Título:
    Future of investigational drugs databases—Part 2 —Comparison of the functionalities and survey of the trend of use— No.2
  • Autor: 21, PINET
  • Assuntos: Asuno Shinyaku ; database comparison ; database on Web version ; exhaustivity ; IDdb ; Integrity ; investigational drug database ; Pharmaprojects ; promptness ; R&D Focus ; R&D Insight ; reliability
  • É parte de: Journal of Information Processing and Management, 2005, Vol.48(1), pp.7-15
  • Descrição: This article traces the trends in the investigational drug databases (the DBs), important information sources for R&D of medical drugs since 2000 when the first survey was conducted, and clarifies the recent trend of the DBs, issues and demands from the users. As the last half part of the whole article, this deals with comparison of exhaustivity, reliability and promptness for IDdb, Integrity (INT), Pharmaprojects (PPJ), R&D Insight (RDI), R&D Focus (RDF) and Asuno Shinyaku by searching those DBs with particular firm names and names of ‘mode of action’. It finds there is no DB which is completely exhaustive although for simple comparison such DBs are likely more exhaustive that covers more chemical compounds on the preclinical test stages, or that has longer period of collecting information. It also finds there are considerable differences among DBs in terms of development stage related information. For searching with names of ‘mode of action’ in keywords specified by each DB, it finds there low search recall occurred over the whole six DBs. There are two reasons why traditional ‘mono-type’ DBs are still used continuously. One is that the coverage of those DBs in terms of clinical test stages related, and well-known investigational drugs is very competitive with large size ‘composite-type’ DBs. The other is that all of the six DBs are not always satisfying in terms of exhausitivity and reliability. The authors propose that each DB vendor should make every effort to improve quality of the basic data even though it moves toward making it available on the Web and making it rather large sized.
  • Editor: Japan Science and Technology Agency
  • Idioma: Japonês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.